Home Daily Stock Opinions and Ratings Novavax Inc (NVAX-Q)

Trending stocks today

MEG Energy Corp Athabasca Oil Sands Corp Arc Resources Ltd Royalty Pharma plc Mercury General Corp iShares 20+ Year Treasury Bond ETF Imperial Oil CASH Cleveland-Cliffs Inc. American Express CME Group Inc Expedia Mastercard Inc. Netflix Inc. Global Ship Lease Inc Equinor ASA Copa Holdings Sprott Inc. Africa Oil Corp.

Novavax Inc (NVAX-Q)

NEW AI Investor Insights
33 watching

NASDAQ:NVAX

7.99
0.18 (2.20%) 1d
Mar 14, 2025, 8:00 pm
0

Related posts

Markets Mixed to end the weekMixed day amid earningsTSX and S&P inch up to new highs
Investor Insights

This summary was created by AI, based on 1 opinions in the last 12 months.

Novavax Inc (NVAX-Q) has faced significant challenges since the onset of the Covid-19 pandemic. Many investors have reported substantial financial losses, which has cast a shadow over the company's market performance. The biotech firm, once considered a frontrunner in vaccine development, has struggled to regain investor confidence as it grapples with operational difficulties and fluctuating stock prices. Analysts highlight the need for a strategic overhaul and clearer communication of the company's future plans to restore faith among stakeholders. Overall, the reviews indicate a cautious outlook and concerns regarding Novavax's ability to rebound in the competitive biotech landscape.

Consensus
Negative
Valuation
Overvalued
DON'T BUY

Novavax Inc(NVAX-Q)

Jun 14, 2024

Since Covid, this has lost too much money for investors.

Jim Cramer - Mad Money
Unknown
Unlock Rating
$14.395

Stock price when the opinion was issued

Pharma & Healthcare
SELL

Novavax Inc(NVAX-Q)

May 11, 2022
Historically not a successful vaccine developer. Shares were $258 last November but fallen to $42. This can fall further. He's never liked it.
Jim Cramer - Mad Money
No
Unlock Rating
$42.900

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

Feb 07, 2022
The variability around earnings makes it interesting to trade, but he would not recommend investing in it. Very volatile. No insight for approval. Prefers using XPI ETF to trade the sector. NVAX is not a name he owns.
Larry Berman CFA, CMT, CTA
No
Unlock Rating
$94.810

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

Jan 26, 2022
The share price and PE have plunged in the past year. Though cheaper to buy, he passes, because they haven't gotten FDA approval for their Covid vaccine.
Jim Cramer - Mad Money
No
Unlock Rating
$79.060

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

Dec 20, 2021
Issued a Covid vaccines that the EU and WHO approved recently. He likes Pfizer in this group; you don't need another one. NVAX is up 6% in the past week.
Jim Cramer - Mad Money
No
Unlock Rating
$202.000

Stock price when the opinion was issued

Pharma & Healthcare
WEAK BUY

Novavax Inc(NVAX-Q)

Dec 07, 2021
Eventually, a full, broad-spectrum vaccine will be in place to cover Covid. Will MRNA technology also develop drugs to tackle TV and HIV and other diseases. Novartis offers more a strong balance sheet and a just-announced $20 billion inflow, based on tuck-in acquisition. NVAX is fine, but there are better companies.
Darren Sissons
Unknown
Unlock Rating
$178.285

Stock price when the opinion was issued

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Novavax Inc(NVAX-Q)

Oct 05, 2021
(A Top Pick Jul 21/21, Down 16.7%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NVAX has triggered its stop at $175. To remain disciplined, we recommend covering the position at this time. Combined with the previous recommendation to cover half the position, this results in a net investment gain of 6%.
The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$170.000

Stock price when the opinion was issued

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

PAST TOP PICK

Novavax Inc(NVAX-Q)

Sep 09, 2021
(A Top Pick Jul 22/21, Up 29.4%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NVAX has achieved its target at $272. To be disciplined, we recommend covering half the position at this time and trailing up the stop (from $160) to $175.
The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$258.850

Stock price when the opinion was issued

Pharma & Healthcare
premium

This is a Panic-proof Portfolio opinion which is available only for Premium members

Curated by Michael O'Reilly since 2020.
1550+ opinions with 4.81 rating (one of the best performing expert).

TOP PICK

Novavax Inc(NVAX-Q)

Jul 22, 2021
Stockchase Research Editor: Michael O'Reilly NVAX is applying for Emergency Use Authorization for its COVID-19 vaccine as experts believe annual boosters may be required as with the annual flu shots. It has achieved over 89% efficacy and does not require deep freeze storage -- a huge advantage. It has agreements already in place for 180 million doses in the UK, Canada, and Australia when approved. We would buy this with a stop loss at $160, looking to achieve $272 -- upside potential over 27%. Yield 0%. (Analysts’ price target is $271.75)
The Panic-Proof Portfolio (Stockchase Research)
Unknown
Unlock Rating
$210.180

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

Jun 15, 2021
Recently announced an effective Covid vaccine In 2019, they had less than $50 million in revenue. It was nascent and now prominent. They could participate in the booster Covid market, and they need to live up to their current market cap of $14 billion. NVAX has to vaccinate a quarter of the world's population to trade at 1x revenues. There's a lot of hope built into the shares that they succeed. He can't buy this and sleep at night.
Gordon Reid
No
Unlock Rating
N/A

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

May 07, 2021

It's not worth what it's selling for, and the stock should be lower. Moderna, in contrast, has more drugs in the pipeline, and he prefers this stock.

Jim Cramer - Mad Money
Unknown
Unlock Rating
$176.050

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

Mar 18, 2021

NVAX vs. PFE He'd absolutely go with PFE. Investors have been chasing growthy parts of the market and ignoring the stable areas. Vaccines don't move the needle for PFE the way they do for the others, but a great long-term investment if you think rates will stay lower. PFE is mature, decent balance sheet, good valuation.

John Zechner
Unknown
Unlock Rating
$219.540

Stock price when the opinion was issued

Pharma & Healthcare
DON'T BUY

Novavax Inc(NVAX-Q)

Jul 24, 2020
There is almost an arms race that is going on with respect to vaccine development. We need to wait to see how human testing is going to work out. There will be lots of volatility in the meantime. He is not interested in playing a specific name -- much like what happened with marijuana stocks. He would look to companies that will provide syringes instead.
Brett Girard, CPA, CA, CFA
No
Unlock Rating
$133.610

Stock price when the opinion was issued

Pharma & Healthcare
Showing 1 to 13 of 13 entries
  • «
  • ‹
  • 1
  • ›
  • »

Novavax Inc(NVAX-Q) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 1

Total Signals / Votes : 1

Stockchase rating for Novavax Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Novavax Inc(NVAX-Q) Frequently Asked Questions

What is Novavax Inc stock symbol?

Novavax Inc is a American stock, trading under the symbol NVAX-Q on the NASDAQ (NVAX). It is usually referred to as NASDAQ:NVAX or NVAX-Q

Is Novavax Inc a buy or a sell?

In the last year, 1 stock analyst published opinions about NVAX-Q. 0 analysts recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Novavax Inc.

Is Novavax Inc a good investment or a top pick?

Novavax Inc was recommended as a Top Pick by on . Read the latest stock experts ratings for Novavax Inc.

Why is Novavax Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Novavax Inc worth watching?

1 stock analyst on Stockchase covered Novavax Inc In the last year. It is a trending stock that is worth watching.

What is Novavax Inc stock price?

On 2025-03-14, Novavax Inc (NVAX-Q) stock closed at a price of $7.99.

Your Watchlist

Add stocks to watchlist to monitor them daily and get important alerts.

Latest Buy Signals

SSL-TSandstorm Gold Ltd.
Sandstorm Gold Ltd.
$9.41
0.11 (1.16%)
HL-NHecla Mining Co
Hecla Mining Co
$5.74
-0.03 (-0.53%)
WCP-TWhitecap Resources
Whitecap Resources
$8.63
0.19 (2.15%)
MGA-TMega Uranium
Mega Uranium
$0.26
0.01 (1.89%)
BTO-TB2Gold Corp.
B2Gold Corp.
$4.26
0.07 (1.62%)
Advertising

Today's Top Picks

AOI-TAfrica Oil Corp.
Africa Oil Corp.
$1.97
0.08 (3.90%)
SII-TSprott Inc.
Sprott Inc.
$61.23
0.95 (1.53%)
CPA-NCopa Holdings
Copa Holdings
$92.78
0.78 (0.83%)
EQNR-NEquinor ASA
Equinor ASA
$24.29
0.51 (2.06%)
GSL-NGlobal Ship Lease Inc
Global Ship Lease Inc
$23.25
0.27 (1.15%)

Popular Articles

Questrade Review: Pros & Cons of Trading with Questrade Canada (2021) Steady Eddys: 3 Stable Stocks Between Safety and Risk: 3 Safe and Gambling Stocks 3 Oversold Stocks to Take Advantage of 5 ETFs for Index Investing

Latest Sell Signals

BCM-XBear Creek Mining
Bear Creek Mining
$0.22
-0.01 (-4.88%)
AMD-QAdvanced Micro Devices
Advanced Micro Devices
$100.97
2.86 (2.75%)
BCE-TBCE Inc.
BCE Inc.
$33.70
-0.46 (-1.39%)
SHOP-TShopify Inc.
Shopify Inc.
$136.33
5.61 (3.95%)
ZWB-TBMO Covered Call Canadian Banks ETF
BMO Covered Call Canadian Banks ETF
$18.69
0.25 (1.32%)

Most Recent Experts

Rule

Rick Rule

Rule Investment Medial

Weiss

Stephen Weiss, Founder, Short Hills Capital Partners

Short Hills Capital Partners

Sechan

Rob Sechan, Managing Partner, New Edge Capital

New Edge Capital

Brown

Josh Brown, CEO, Ritholtz Wealth Management

Ritholtz Wealth Management

Raskin

Amy Raskin, CIO, Chevy Chase Trust

Chevy Chase Trust

Advertising
Advertising
logoTop pickslogoStockslogoRecentlogoWatchlist
© Stockchase Inc.